Modality
Nanobody
MOA
USP1i
Target
TIGIT
Pathway
Epigenetic
FTDPsoriasis
Development Pipeline
Preclinical
May 2020
→ Dec 2028
PreclinicalCurrent
NCT07483615
2,110 pts·FTD
2022-12→2025-11·Not yet recruiting
NCT04074394
1,983 pts·Psoriasis
2020-05→2028-12·Not yet recruiting
4,093 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-10-195mo agoNDA· FTD
2025-11-254mo agoInterim· FTD
2028-12-252.7y awayInterim· Psoriasis
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Not yet…
Preclinical
Not yet…
Catalysts
NDA
2025-10-19 · 5mo ago
FTD
Interim
2025-11-25 · 4mo ago
FTD
Interim
2028-12-25 · 2.7y away
Psoriasis
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07483615 | Preclinical | FTD | Not yet recr... | 2110 | NT-proBNP |
| NCT04074394 | Preclinical | Psoriasis | Not yet recr... | 1983 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |